Why promising molecules often disappoint: oxytocin, supplements and semaglutide
September 29, 2026 · 19 min read
Oxytocin failed in autism trials while vasopressin showed promise, anti-aging supplements remain debated, and semaglutide works by pharmacology rather than natural physiology. These cases show how hard it is to turn an elegant biological mechanism into a treatment that actually helps people.
The rules, numbers and steps worth keeping in front of you.
- A well-understood mechanism is not proof a molecule helps patients; dose, delivery, patient selection and large trials decide.
- Karen Parker: a large multi-site trial of oxytocin for autism found no benefit.
- Parker: oxytocin helped children with the lowest baseline levels most, and may work best in young children.
- Parker: her vasopressin trial was a small pilot of 30 children; a larger trial is being completed.
- Parker: do not obtain vasopressin on your own, because of its blood pressure effects.
- Parker: about half of drugs that work in animals but fail in humans trace to poorly chosen animal models.
- Zachary Knight: food might change GLP-1 about twofold; the drugs reach a thousand to ten thousand times natural levels.
- Knight: drugs that raise natural GLP-1 threefold treat diabetes but do not cause weight loss.
- Knight: semaglutide lasts seven days and produces about 16 percent weight loss over roughly a year.
- Knight: leptin failed as an obesity drug because most obese people are already leptin resistant.
- Knight: 25 to 33 percent of weight lost is typically muscle unless you eat enough protein and resistance train.
- David Sinclair's supplement evidence is largely from mice or unpublished; he describes his own practice, not recommendations.
- Treat unpublished data as a hypothesis, not a finding.
- Prescription drugs, children with autism, supplement stacks: get a physician's guidance.
This is the short form. The full insight has every expert's reasoning, their own words and the sources.